Compare Tyson Foods, Inc. (TSN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tyson Foods, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Tyson Foods, Inc. trades at $54.25 (market cap $18.92B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Tyson Foods, Inc. is far larger — about 3.9× Travere Therapeutics Inc. Common Stock's market cap, and Tyson Foods, Inc. pays a 3.79% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tyson Foods, Inc. for 77 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TSN | TVTX | |
|---|---|---|
Market Cap | $18.92B | $4.88B |
Volume | 2,968,585 | 1,668,577 |
Sector | Consumer Staples | Health |
52-Week High | $68.75 | $67.52 |
52-Week Low | $50.47 | $26.79 |
Typical Hold Time | 77 Days | 0 Days |
Enterprise Value | $26.19B | $5.01B |
Dividend Yield | 3.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tyson Foods (TSN) trades at $54.22, up 1.21% with a bullish technical signal despite recent volatility. The stock shows mixed earnings performance with two beats and one miss in recent quarters, while maintaining a 53% analyst buy rating. Current valuation metrics include a P/E of 33.2 and P/S of 0.34, with revenue growth projected to $55.7B in 2026. Recent corporate actions include consistent dividend payments of $0.51 per share.
Outlook remains cautiously optimistic with a $65.40 consensus price target representing 21% upside potential. Key risks include ongoing beef segment losses, securities investigations, and margin pressure. The company's ability to maintain dividends while addressing operational challenges will be critical for sustained shareholder value.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
